HALO
No price yet
Announcements
Nothing here yet
Daily updates
Nothing here yet
FDA designations
Nothing here yet
News
- FDA approves RYBREVANT FASPRO™ co-formulated with ENHANZE® for EGFR-mutated NSCLCDec 18, 2025
- FDA approved DARZALEX Faspro® for adult patients with high-risk smoldering multiple myelomaNov 7, 2025
- Halozyme to acquire Elektrofi, expanding offerings in innovative drug delivery and strengthening long-term growth into 2040sOct 1, 2025
- Halozyme announces European approval for VYVGART® subcutaneous injection with ENHANZE® for CIDPJun 23, 2025
- Halozyme announces European Commission approval of Bristol Myers Squibb's subcutaneous Opdivo® (nivolumab) co-formulated with ENHANZE® for multiple solid tumorsMay 28, 2025